other material
confidence high
sentiment positive
materiality 0.80
Denali Therapeutics receives $200M from Royalty Pharma after FDA approval of tividenofusp alfa
Denali Therapeutics Inc.
- Received $200.0M gross proceeds from Royalty Pharma under synthetic royalty funding agreement.
- Closing followed FDA accelerated approval of tividenofusp alfa on March 24, 2026.
- Synthetic royalty agreement was previously announced on December 4, 2025.
- Proceeds provide non-dilutive capital for further development and commercialization.